OncoZenge to present BupiZenge Phase III program at Pain Therapeutics Summit

• OncoZenge will present its Phase III BupiZenge program at the Pain Therapeutics Summit on Sept. 28-29 in the San Francisco Bay Area.
• Presentation will focus on BupiZenge for oral pain linked to oral mucositis in patients receiving cancer treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.